Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Enanta Pharmaceuticals, Inc.”

218 pharma patents match "Enanta Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 218
Index total 30,257
Page 5 / 10

Quick answer

This filtered view shows 218 pharmaceutical patents matching "Enanta Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

218 results for “Enanta Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9732110

    Nucleoside and nucleotide derivatives

    Enanta Pharmaceuticals, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted

  2. US 9718851

    Deuterated nucleoside/tide derivatives

    Enanta Pharmaceuticals, Inc. · Granted Aug 1, 2017 · Expires Jul 27, 2037

    granted

  3. US 9676802

    Hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted

  4. US 9675632

    Nucleoside and nucleotide derivatives

    Enanta Pharmaceuticals, Inc. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted

  5. US 9669095

    Cyclosporin analogues for preventing or treating hepatitis C infection

    Enanta Pharmaceuticals, Inc. · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted

  6. US 9616099

    Cyclosporin analogues for preventing or treating hepatitis C infection

    Enanta Pharmaceuticals, Inc. · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted

  7. US 9603895

    Cyclosporin analogues for preventing or treating hepatitis C infection

    Enanta Pharmaceuticals, Inc. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted

  8. US 9526769

    Macrocylic oximyl hepatitis C protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Dec 27, 2016 · Expires Dec 22, 2036

    granted

  9. US 9309279

    Macrocyclic hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Apr 12, 2016 · Expires Apr 7, 2036

    granted

  10. US 9221878

    Cyclosporin analogues for preventing or treating hepatitis C infection

    Enanta Pharmaceuticals, Inc. · Granted Dec 29, 2015 · Expires Dec 24, 2035

    granted

  11. US 9220748

    Macrocyclic proline derived HCV serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Dec 29, 2015 · Expires Dec 24, 2035

    granted

  12. US 9193740

    Bismacrocyclic compounds as hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Nov 24, 2015 · Expires Nov 19, 2035

    granted

  13. US 9156818

    Hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Oct 13, 2015 · Expires Oct 8, 2035

    granted

  14. US 9156886

    Cyclosporin analogues for preventing or treating hepatitis C infection

    Enanta Pharmaceuticals, Inc. · Granted Oct 13, 2015 · Expires Oct 8, 2035

    granted

  15. US 9127021

    Hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Sep 8, 2015 · Expires Sep 3, 2035

    granted

  16. US 9085599

    2′allene-substituted nucleoside derivatives

    Enanta Pharmaceuticals, Inc. · Granted Jul 21, 2015 · Expires Jul 16, 2035

    granted

  17. US 9060971

    Combination pharmaceutical agents as inhibitors of HCV replication

    Enanta Pharmaceuticals, Inc. · Granted Jun 23, 2015 · Expires Jun 18, 2035

    granted

  18. US 9000020

    Linked dibenzimidazole antivirals

    Enanta Pharmaceuticals, Inc. · Granted Apr 7, 2015 · Expires Apr 2, 2035

    granted

  19. US 8962551

    Quinoxalinyl derivatives

    Enanta Pharmaceuticals, Inc. · Granted Feb 24, 2015 · Expires Feb 19, 2035

    granted

  20. US 8951998

    Quinoxaline-containing compounds as hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Feb 10, 2015 · Expires Feb 5, 2035

    granted

  21. US 8951964

    Phenanthridine macrocyclic hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Feb 10, 2015 · Expires Feb 5, 2035

    granted

  22. US 8940688

    Fluorinated tripeptide HCV serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Jan 27, 2015 · Expires Jan 22, 2035

    granted

  23. US 8936781

    Macrocyclic compounds as hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Jan 20, 2015 · Expires Jan 15, 2035

    granted

  24. US 8933110

    Hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Jan 13, 2015 · Expires Jan 8, 2035

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.